Technical Analysis for LOXO - Loxo Oncology, Inc.

Grade Last Price % Change Price Change
grade A 234.66 0.00% 0.00
LOXO closed down 0.03 percent on Thursday, February 14, 2019, on 67 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Flat
See historical LOXO trend table...

Date Alert Name Type % Chg
Jan 8 New Uptrend Bullish 1.02%
Jan 8 Volume Surge Other 1.02%
Jan 8 Calm After Storm Range Contraction 1.02%
Jan 8 Narrow Range Bar Range Contraction 1.02%
Jan 8 NR7 Range Contraction 1.02%
Jan 8 NR7-2 Range Contraction 1.02%
Jan 8 Parabolic Rise Strength 1.02%
Jan 8 Stochastic Reached Overbought Strength 1.02%
Jan 8 Upper Bollinger Band Walk Strength 1.02%
Jan 8 Inside Day Range Contraction 1.02%

Older signals for LOXO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Loxo Oncology, Inc., a development-stage company, develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its lead product candidate includes LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase, which is in a Phase I dose escalation trial for the treatment of patients with advanced solid tumor types, such as neuroblastoma and lung, thyroid, and breast cancers. The company is also developing a pipeline of additional product candidates targeting cancers driven by genetic alterations. Loxo Oncology, Inc. has a drug discovery collaboration agreement with Array BioPharma Inc. The company was founded in 2013 and is headquartered in Stamford, Connecticut.
Cancer Nasdaq Organ Systems Treatment Of Cancer Oncology Cancers Drug Discovery Neuroblastoma Tyrosine Kinase Receptors Breast Cancers Array Biopharma Trk Receptor
Is LOXO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 234.93
52 Week Low 103.5
Average Volume 1,157,324
200-Day Moving Average 170.4927
50-Day Moving Average 190.8506
20-Day Moving Average 234.1995
10-Day Moving Average 234.602
Average True Range 2.2139
ADX 64.73
+DI 49.9503
-DI 8.5995
Chandelier Exit (Long, 3 ATRs ) 228.2883
Chandelier Exit (Short, 3 ATRs ) 239.1517
Upper Bollinger Band 235.1494
Lower Bollinger Band 233.2496
Percent B (%b) 0.74
BandWidth 0.811189
MACD Line 10.3677
MACD Signal Line 13.487
MACD Histogram -3.1192
Fundamentals Value
Market Cap 7 Billion
Num Shares 29.8 Million
EPS -4.18
Price-to-Earnings (P/E) Ratio -56.14
Price-to-Sales 0.00
Price-to-Book 5.55
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 234.99
Resistance 3 (R3) 235.03 234.95 234.94
Resistance 2 (R2) 234.95 234.87 234.94 234.92
Resistance 1 (R1) 234.81 234.82 234.77 234.77 234.90
Pivot Point 234.73 234.73 234.72 234.72 234.73
Support 1 (S1) 234.59 234.65 234.55 234.55 234.42
Support 2 (S2) 234.51 234.60 234.50 234.40
Support 3 (S3) 234.37 234.51 234.39
Support 4 (S4) 234.33